Clinical Trials

Device Accountability for Imported Investigational Devices: Shipment, Disposition, and FDA Records

By Andre D. Butler, medical device regulatory consultant, CQA, CCRP  ·  reviewed November 2026  ·  ← All Insights

Device Accountability for Imported Investigational Devices: Shipment, Disposition, and FDA Records

Photo by Markus Winkler on Unsplash

The foundational rule: why a US Sponsor of Record is required

Under 21 CFR 812.18(a), a company located outside the United States cannot itself hold an FDA Investigational Device Exemption (IDE) as sponsor. A US person or entity must assume the sponsor role and bear full regulatory responsibility for the investigational device study conducted in the United States. This requirement is not a formality. The moment an investigational device crosses the US border, the designated US Sponsor of Record becomes the accountable party for every unit shipped, used, and ultimately disposed of under the IDE. For non US device manufacturers seeking a US clinical pathway, the choice of sponsor structure and the rigor of accountability systems put in place before first shipment can define the trajectory of the entire program.

What device accountability actually means

Device accountability is the continuous, documented chain of custody that connects every investigational unit from its initial shipment into the United States through distribution to investigational sites, use in human subjects, and final disposition by return or destruction. It covers shipment verification, site level receipt confirmation, per subject use recording, and the closure of each unit's status at study end. When FDA reviews an IDE or conducts a site inspection, it expects to reconstruct the fate of every unit without gaps.

Labeling: the first accountability touchpoint

Before an investigational device leaves its country of manufacture, labeling must comply with 21 CFR 812.5. That regulation requires the device to bear a specific caution statement indicating it is an investigational device limited by federal law to investigational use, along with the name and address of the manufacturer and any applicable directions for use or handling conditions. Labeling deficiencies identified at the border or at a clinical site are among the most avoidable IDE compliance failures, yet they appear with notable frequency in FDA inspection observations. The US Sponsor of Record is responsible for confirming that labeling requirements are met before distribution, not after a 483 observation prompts a correction.

The records FDA expects: a practical breakdown

21 CFR 812.140(b) states that 'a sponsor shall maintain accurate, complete, and current records relating to an investigation,' and those records must be retained for a period following the termination or completion of the investigation. See 21 CFR 812.140(b) on eCFR. For imported investigational devices specifically, the records framework should include the following categories.

  • Shipment logs: Records generated at the point of export and import, including commercial invoices, customs entry documents, packing lists, and shipping confirmations. Each log should identify device type, lot or serial numbers, quantity shipped, ship date, carrier, and the receiving site. The US Sponsor of Record should receive copies of all inbound shipment documentation as a matter of standard operating procedure.
  • Site level receipt records: At each investigational site, the site coordinator or designee must acknowledge receipt of investigational devices and confirm that quantities received match shipment documentation. Any discrepancies, including damaged units or short shipments, must be documented and communicated to the sponsor immediately. These records form the opening balance of the site device accountability log.
  • Use records: Every investigational device used in a human subject must be traceable to a specific subject or procedure record. Use records should capture the device identifier, the subject identifier (using the study code, not personal health information in sponsor records), the date of use, the site, and the name of the investigator. For implantable devices, these records carry additional significance given post market traceability requirements that may follow IDE approval.
  • Final disposition records: At study closure, every unit must be accounted for. Units used in subjects are closed out through use records. Unused units must be either returned to the sponsor or the manufacturer, or destroyed under a documented destruction protocol. Return shipment manifests and destruction certificates become part of the permanent IDE record and should be retained in accordance with 21 CFR 812.140(b) timelines.

Practical considerations for non US manufacturers structuring a US study

Non US device companies often underestimate the operational burden of device accountability when they begin planning a US IDE study. Building a compliant accountability system requires early assessment of your supply chain, your contract research organization's capabilities, and the accountability procedures already in place at your planned investigational sites. ADB's regulatory team works with clients to review existing procedures and prepare accountability frameworks that are appropriate for the device type, IDE risk classification (whether the study involves a significant risk or nonsignificant risk device determination), and the number of sites involved. The correct structure for a single site feasibility study differs substantially from a pivotal multicenter trial, and the accountability records should reflect that scope from day one. Learn more about how ADB supports sponsors at adbccro.com/clinical-trial-services.

If you are assessing whether your organization is prepared to assume sponsor obligations, start with ADB's structured review tools: the US Sponsor Obligations Checklist and the US Sponsor Decision Tool can help your team identify gaps before they become inspection findings.

Closing: take the next step with ADB

ADB Consulting and CRO Inc. serves as US Sponsor of Record for non US medical device companies seeking to conduct FDA regulated investigational studies in the United States. If your team is preparing to initiate an IDE study or reviewing your current accountability procedures in advance of an FDA inspection, ADB's regulatory team is ready to assess your program and prepare a path forward. Book a free discovery call at adbccro.com and connect with the team today.

Reviewed November 21, 2026 by ADB's regulatory team.

Frequently asked questions

Can a non US company be listed as the IDE sponsor if it has a US subsidiary?

A US subsidiary that is a legally distinct US entity may be eligible to serve as sponsor under 21 CFR 812.18(a), provided it assumes genuine regulatory responsibility and is not acting as a pass-through for the foreign parent. FDA looks at the substance of the arrangement, not just the corporate structure. ADB's regulatory team can review your corporate structure and assess whether a subsidiary designation or a formal US Sponsor of Record arrangement is the more appropriate and defensible approach for your program.

How long must device accountability records be retained after an IDE study closes?

Under 21 CFR 812.140(b), sponsors must retain IDE records for a period of two years after the latter of the following: the date on which the investigation is terminated or completed, or the date that the records are no longer required to support a premarket approval application or a notice of completion of a product development protocol. For devices that proceed to a PMA submission, the retention obligation extends accordingly. Sponsors should prepare a retention schedule at the outset of the study rather than making retention decisions after study closure.

What happens if a discrepancy is found between shipped and received quantities?

Any discrepancy between units shipped and units received at a site must be investigated, documented, and resolved in writing. Depending on the nature of the discrepancy, the US Sponsor of Record may have reporting obligations under 21 CFR 812.150 if the discrepancy is associated with a device malfunction or an adverse event. Even when no reportable event is involved, unresolved accountability gaps are a significant inspection finding. ADB recommends that sponsors prepare and implement a written discrepancy investigation procedure as part of the IDE device accountability system before first shipment.

Related reading: our clinical trial data management support covers this in more depth.

Prepared by ADB's Regulatory Team

Reviewed by Andre D. Butler, medical device regulatory consultant, CQA, CCRP

ADB's regulatory team brings 20+ years of hands-on FDA regulatory experience guiding medical device companies through 510(k), PMA, De Novo, AI/ML SaMD, and FDA 483 response engagements, with specialization in Section 524B cybersecurity compliance and ISO 13485 quality management systems across cardiovascular, orthopedic, diagnostic, and software-as-a-medical-device categories.

Ready to Navigate the FDA Process with Confidence?

Book a free 30-minute discovery call with ADB's regulatory team to discuss your specific device and situation.

Book a Free Pathway Call

Or call directly: (888) 450-8607

Explore our flat-fee FDA services →